NovAccess Global to Participate in LD Micro Invitational XII Conference

CLEVELAND, OH / ACCESSWIRE / May 19, 2022 /NovAccess Global Inc. (OTC PINK:XSNX) announced that its Chief Executive Officer Dr. Dwain Irvin is scheduled to participate in the LD Micro Invitational XII Conference on June 7-9, 2022. The conference is being held at the Four Seasons Hotel Westlake Village near Los Angeles, CA. This will be an in-person conference with NovAccess Global presenting on Tuesday, June 7, 2022, at 4:00 pm pacific time in Track 4 and hosting 1:1 meetings with investors throughout the day.

Presentation materials will be made available on the morning of June 7 on the Investor Relations section of the Company's website. Investors interested in meeting with NovAccess Global should contact LD Micro or Jordan Darrow of Darrow Associates, IR for the Company, at jdarrow@darrowir.com.

NovAccess Global is a translational biotechnology company developing novel immunotherapies for brain tumor patients, featuring recently approved United States patent #US9764014B2. The patent is granted under the "Cancer Antigens" category and related to the "treatment of cancer using vaccination therapy." The Company is working on future milestones of getting uplisted on OTCQB, filing for orphan drug status, and filing for Phase IIa IND application with FDA.

About NovAccess Global

NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treat brain tumor patients with glioblastoma multiforme, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. The Company owns a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight existing cancer by strengthening the body's natural defenses against the cancer cells. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.

Forward-Looking Statement

This email and its attachments contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude or risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission and/or OTC Markets, Inc. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess, Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.

Investor Relations Contact:

Jordan Darrow
Darrow Associates
631-766-4528
jdarrow@darrowir.com

SOURCE:NovAccess Global Inc.

View source version on accesswire.com:
https://www.accesswire.com/702014/NovAccess-Global-to-Participate-in-LD-Micro-Invitational-XII-Conference

© 2022 Accesswire. All Rights Reserved.